A detailed history of Flc Capital Advisors transactions in Abb Vie Inc. stock. As of the latest transaction made, Flc Capital Advisors holds 4,772 shares of ABBV stock, worth $855,142. This represents 0.22% of its overall portfolio holdings.

Number of Shares
4,772
Previous 5,717 16.53%
Holding current value
$855,142
Previous $980,000 3.88%
% of portfolio
0.22%
Previous 0.24%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$163.84 - $199.33 $154,828 - $188,366
-945 Reduced 16.53%
4,772 $942,000
Q2 2024

Jul 15, 2024

SELL
$154.79 - $180.76 $160,981 - $187,990
-1,040 Reduced 15.39%
5,717 $980,000
Q1 2024

May 03, 2024

SELL
$159.82 - $182.1 $21,575 - $24,583
-135 Reduced 1.96%
6,757 $1.23 Million
Q4 2023

Jan 18, 2024

SELL
$137.6 - $154.97 $8,256 - $9,298
-60 Reduced 0.86%
6,892 $1.07 Million
Q3 2023

Jan 18, 2024

SELL
$133.59 - $154.65 $10,687 - $12,372
-80 Reduced 1.14%
6,952 $1.04 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $132,510 - $164,900
-1,000 Reduced 12.45%
7,032 $947,000
Q1 2023

Apr 26, 2023

SELL
$144.61 - $166.54 $331,735 - $382,042
-2,294 Reduced 22.22%
8,032 $1.28 Million
Q4 2022

Jan 27, 2023

SELL
$138.31 - $165.87 $89,901 - $107,815
-650 Reduced 5.92%
10,326 $1.67 Million
Q3 2022

Oct 14, 2022

SELL
$134.21 - $153.93 $196,617 - $225,507
-1,465 Reduced 11.78%
10,976 $1.47 Million
Q1 2022

Apr 25, 2022

SELL
$131.98 - $163.75 $46,193 - $57,312
-350 Reduced 2.74%
12,441 $2.02 Million
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $66,391 - $84,004
-618 Reduced 4.61%
12,791 $1.73 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $8,416 - $9,376
80 Added 0.6%
13,409 $1.51 Million
Q1 2021

Apr 23, 2021

BUY
$102.3 - $112.62 $10,230 - $11,262
100 Added 0.76%
13,329 $1.44 Million
Q4 2020

Feb 10, 2021

BUY
$80.49 - $108.67 $69,140 - $93,347
859 Added 6.94%
13,229 $1.42 Million
Q3 2020

Oct 23, 2020

BUY
$85.91 - $100.83 $124,655 - $146,304
1,451 Added 13.29%
12,370 $1.04 Million
Q2 2020

Jul 10, 2020

BUY
$73.37 - $98.18 $111,008 - $148,546
1,513 Added 16.09%
10,919 $1.08 Million
Q1 2020

Apr 09, 2020

BUY
$64.5 - $97.79 $237,360 - $359,867
3,680 Added 64.27%
9,406 $707,000
Q4 2019

Jan 13, 2020

SELL
$72.13 - $90.25 $18,825 - $23,555
-261 Reduced 4.36%
5,726 $507,000
Q3 2019

Oct 29, 2019

SELL
$62.98 - $75.72 $45,597 - $54,821
-724 Reduced 10.79%
5,987 $453,000
Q2 2019

Aug 05, 2019

BUY
$65.7 - $83.98 $64,977 - $83,056
989 Added 17.28%
6,711 $478,000
Q1 2019

May 13, 2019

BUY
$77.14 - $90.79 $59,860 - $70,453
776 Added 15.69%
5,722 $461,000
Q4 2018

Feb 11, 2019

BUY
$77.85 - $96.01 $385,046 - $474,865
4,946 New
4,946 $456,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Flc Capital Advisors Portfolio

Follow Flc Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flc Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Flc Capital Advisors with notifications on news.